论文部分内容阅读
目的:评价自体骨髓间充质干细胞移植治疗心绞痛的安全性和有效性。方法:40例心绞痛患者,分为观察组与对照组各20例。观察组在接受常规药物治疗和经皮冠状动脉介入治疗后,行冠状动脉内自体骨髓间充质干细胞移植,对照组仅接受常规药物治疗和经皮冠状动脉介入治疗。2组在术前和术后6个月行二维超声、单光子体层扫描和动态心电图检测;在术中、术后3,6个月观察2组是否有心肌梗死、心律失常等并发症,并评价疗效。结果:观察组心绞痛发作频率、硝酸甘油用量、运动时间及加拿大心血管学会心绞痛分级明显优于对照组(P<0.05)。与对照组比较,观察组灌注缺损明显减小(P<0.01)。2组均无心肌梗死、心律失常及其他不良事件发生。结论:冠状动脉内注射自体骨髓间充质干细胞治疗心绞痛安全有效。
Objective: To evaluate the safety and efficacy of autologous bone marrow mesenchymal stem cell transplantation in the treatment of angina pectoris. Methods: 40 patients with angina pectoris were divided into observation group and control group, 20 cases each. The patients in the observation group received autologous bone marrow mesenchymal stem cells transplantation after receiving conventional drug therapy and percutaneous coronary intervention. The control group received routine drug treatment and percutaneous coronary intervention. Two groups were examined preoperatively and 6 months after operation by two-dimensional ultrasound, single photon tomography and Holter monitoring. The complications of myocardial infarction and cardiac arrhythmia were observed in 2 and 6 months postoperatively , And evaluate the efficacy. Results: The frequency of angina pectoris, the amount of nitroglycerin, exercise time and angina pectoris score of the Canadian Cardiovascular Society were significantly better in the observation group than those in the control group (P <0.05). Compared with the control group, the observation group, the perfusion defect was significantly reduced (P <0.01). No myocardial infarction, arrhythmia and other adverse events occurred in both groups. Conclusion: Intracoronary injection of autologous bone marrow mesenchymal stem cells in the treatment of angina pectoris is safe and effective.